1. A method of treating or preventing at least one inflammatory condition in a patient, comprising administering to the patient an amount of an RARγ agonist sufficient to inhibit activation of type I NKT cells. The method according to claim 1, characterized in that the inflammatory condition is selected from the group consisting of fatty liver disease, alcohol-induced hepatitis, non-alcoholic steatosis hepatitis, cirrhosis, acute cirrhosis, idiopathic hepatitis, viral hepatitis (A, B, C and others), inflammatory hepatitis associated with hepatobiliary carcinoma, multiple sclerosis, type 1 diabetes mellitus, ischemic reperfusion injury, solid organ transplantation, systemic lupus erythematosus, rheumatoid arthritis, amyotrophic lateral sclerosis and inflammatory bowel disease (Crohn's disease and colitis) .3. The method according to claim 1, characterized in that the RARγ agonist comprises tazarotene. The method of claim 1, further comprising administering an amount of sulfatide or a synthetic analog of sulfatide sufficient to activate type II NKT cells. The method according to claim 4, characterized in that a sulfatide having the following chemical structure is introduced: where R is selected from the group consisting of hydrogen, C-C1-6alkyl, substituted C-C1-6alkyl, C-alkkenyl, substituted C-alkkenyl and C-Ccaxapa ； R is selected from the group consisting of hydrogen, a hydroxy group, a methoxy group and an alkoxy group； R is selected from the group consisting of hydrogen, a hydroxy group, a methoxy group, an ethoxy group and an alkoxy group； R is selected from the group consisting of hydrogen, a hydroxy group and an alkoxy group； R is selected from the group consisting of hydrogen, hydroxyl, carbonyl, alkoxy, and1. Способ лечения или предупреждения по меньшей мере одного воспалительного состояния у пациента, включающий введение пациенту количества агониста RARγ, достаточного для ингибирования активации NKT-клеток I типа.2. Способ по п.1, отличающийся тем, что вос
